However, only a subgroup of patients treated with cetuximab benefits from the drug.3 The detailed picture of downstream pathways deregulated in EGFR signaling remains unclear and needs to be elucidated to understand cancer pathogenesis and develop efficient treatments.4 This evidence concerns the gene EGFR and cancer.